Key Highlights

  • Phase 3 data on INCB161734 in KRAS G12D-mutated pancreatic cancer due October 24.
  • Separate Phase 3 data on INCB123667 plus bevacizumab in ovarian cancer due October 26.
  • Programs are known as DAWN-303 and MAESTRA 3/GOG-3146/ENGOT-OV106, respectively.
  • Incyte shares trade near $117.25, with a market value of about $23.42 billion.

Incyte Corporation (NASDAQ: INCY) is scheduled to present two separate Phase 3 oncology readouts at the ESMO 2026 congress, covering candidates in pancreatic cancer and ovarian cancer.

What Happened

The first program, INCB161734, is being studied in previously untreated, KRAS G12D-mutated metastatic pancreatic ductal adenocarcinoma under the DAWN-303 trial, with Phase 3 data scheduled for ESMO on October 24, 2026.

The second program, INCB123667, a CDK2 inhibitor combined with bevacizumab, is being studied versus bevacizumab alone in advanced epithelial ovarian and fallopian tube cancer, under the MAESTRA 3 (GOG-3146; ENGOT-OV106) trial. That Phase 3 study is ongoing, with data scheduled for ESMO on October 26, 2026.

Market Reaction

Incyte, a large-cap biopharmaceutical company valued at approximately $23.42 billion, traded near $117.25 per share, up $0.60, or 0.51%, according to the disclosed pipeline database.

Outlook

Phase 3 data for INCB161734 in pancreatic cancer is scheduled for October 24, 2026, while Phase 3 data for INCB123667 in ovarian cancer is scheduled for October 26, 2026, both at the ESMO congress.

What cancer types are Incyte's two ESMO readouts covering?

One Phase 3 readout covers KRAS G12D-mutated metastatic pancreatic cancer (INCB161734), and the other covers advanced epithelial ovarian and fallopian tube cancer (INCB123667).

When will Incyte present its pancreatic cancer data?

Phase 3 data on INCB161734 in the DAWN-303 trial is scheduled for ESMO on October 24, 2026.

When will Incyte present its ovarian cancer data?

Phase 3 data on INCB123667 in the MAESTRA 3 trial is scheduled for ESMO on October 26, 2026.